Fig 2.

(A,B) A 52-year-old woman with a history of right breast invasive ductal malignancy, status post lumpectomy and radiation, presented for routine yearly screening mammogram, 22 days after her second dose of the Moderna coronavirus disease 2019 (COVID-19) vaccination in the left deltoid muscle. (A) Left mediolateral oblique mammographic view demonstrated a single prominent lymph node in the left axilla (arrow), which was more prominent compared with (B) screening mammography performed 1 year previously. (C-E) A 33-year-old woman with a family history of breast cancer presented for baseline high-risk screening breast MRI, 1 day after her second dose of the Moderna COVID-19 vaccine in the left deltoid muscle. Multiple enlarged left axillary level 1 and 2 lymph nodes (arrows) were noted on the (C) 3-D axial maximum-intensity projection, (D) T1-weighted fat-saturated postcontrast axial, and (E) sagittal images. In both patients, the left axillary lymphadenopathy was an isolated finding with no abnormality in the bilateral breasts. Given recent COVID-19 vaccination, the cases were interpreted as BI-RADS category 2 (benign). The report impression stated, “Enlarged lymph nodes in the left axilla are benign. In the specific setting of the patient’s documented recent (within 6 weeks) COVID-19 vaccination in the ipsilateral arm, axillary adenopathy is a benign imaging finding. No further imaging is indicated at this time. If there is clinical concern that persists more than 6 weeks after the patient’s final vaccine dose, axillary ultrasound is recommended.”